Uroxatral Side Effects

Generic Name: alfuzosin

Note: This document contains side effect information about alfuzosin. Some of the dosage forms listed on this page may not apply to the brand name Uroxatral.

Some side effects of Uroxatral may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to alfuzosin: oral tablet extended release

Along with its needed effects, alfuzosin (the active ingredient contained in Uroxatral) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking alfuzosin:

Rare
  • Chest pain
  • chills
  • cold sweats
  • confusion
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • painful or prolonged erection of the penis
Incidence not known
  • Arm, back, or jaw pain
  • chest discomfort
  • chest tightness or heaviness
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • nausea
  • shortness of breath
  • sweating
  • swelling

Some side effects of alfuzosin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Dizziness
Less common
  • Abdominal or stomach pain
  • acid or sour stomach
  • belching
  • body aches or pain
  • congestion
  • cough
  • cough producing mucus
  • decreased interest in sexual intercourse
  • difficulty breathing
  • difficulty having a bowel movement (stool)
  • dryness or soreness of the throat
  • ear congestion
  • fever
  • headache
  • heartburn
  • hoarseness
  • inability to have or keep an erection
  • indigestion
  • loss in sexual ability, desire, drive, or performance
  • loss of voice
  • nasal congestion
  • pain
  • pain or tenderness around the eyes and cheekbones
  • sneezing
  • sore throat
  • stomach discomfort, upset, or pain
  • stuffy or runny nose
  • tender, swollen glands in the neck
  • tightness in the chest
  • trouble with swallowing
  • unusual tiredness or weakness
  • voice changes
  • wheezing
Rare
  • Rash
Incidence not known
  • Diarrhea
  • feeling of warmth
  • hives or welts
  • itching skin
  • redness of the skin
  • redness of the face, neck, arms, and occasionally, upper chest

For Healthcare Professionals

Applies to alfuzosin: oral tablet extended release

Nervous system

Very common (10% or more): Dizziness (up to 27%), headache (up to 14%), fatigue (up to 14%)
Common (1% to 10%): Syncope, pain
Postmarketing reports: Flushing

Respiratory

Very common (10% or more): Upper respiratory tract infection (up to 14%)
Common (1% to 10%): Bronchitis, sinusitis, pharyngitis
Postmarketing reports: Rhinitis

Cardiovascular

Common (1% to 10%): Hypotension or postural hypotension
Postmarketing reports: Tachycardia, chest pain, angina pectoris in patients with preexisting coronary artery disease, atrial fibrillation

Gastrointestinal

Common (1% to 10%): Abdominal pain, dyspepsia, constipation, nausea
Postmarketing reports: Diarrhea

Genitourinary

Common (1% to 10%): Impotence
Postmarketing reports: Priapism

Ocular

Frequency not reported: Intraoperative Floppy Iris Syndrome (IFIS) has been observed in some patients undergoing phacoemulsification cataract surgery while being treated with alpha-1 blockers

Hepatic

Postmarketing reports: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)

Dermatologic

Postmarketing reports: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis

Hematologic

Postmarketing reports: Thrombocytopenia

Metabolic

Postmarketing reports: Edema

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web1)